US 11,986,529 B2
Pharmaceutical compositions and related methods of delivery
Roni Mamluk, Mazkeret Batya (IL); Moshe Tzabari, Jerusalem (IL); Karen Marom, Mevaseret Zion (IL); Paul Salama, Ashdod (IL); and Irina Weinstein, Maale Adummim (IL)
Assigned to Amryt Endo, Inc., Boston, MA (US)
Filed by Amryt Endo, Inc., Needham, MA (US)
Filed on Aug. 2, 2022, as Appl. No. 17/879,441.
Application 17/879,441 is a continuation of application No. 17/847,012, filed on Jun. 22, 2022, abandoned.
Application 17/847,012 is a continuation of application No. 16/990,071, filed on Aug. 11, 2020, granted, now 11,400,159, issued on Aug. 2, 2022.
Application 16/990,071 is a continuation of application No. 15/981,423, filed on May 16, 2018, abandoned.
Application 15/981,423 is a continuation of application No. 15/397,177, filed on Jan. 3, 2017, abandoned.
Application 15/397,177 is a continuation of application No. 15/044,949, filed on Feb. 16, 2016, granted, now 9,566,246, issued on Feb. 14, 2017.
Application 15/044,949 is a continuation of application No. 14/188,139, filed on Feb. 24, 2014, granted, now 9,265,812, issued on Feb. 23, 2016.
Application 14/188,139 is a continuation of application No. 12/981,036, filed on Dec. 29, 2010, abandoned.
Application 12/981,036 is a continuation of application No. 12/561,738, filed on Sep. 17, 2009, abandoned.
Claims priority of provisional application 61/161,387, filed on Mar. 18, 2009.
Claims priority of provisional application 61/141,686, filed on Dec. 31, 2008.
Claims priority of provisional application 61/097,716, filed on Sep. 17, 2008.
Prior Publication US 2022/0370622 A1, Nov. 24, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/44 (2017.01); A61K 9/00 (2006.01); A61K 9/10 (2006.01); A61K 9/48 (2006.01); A61K 31/70 (2006.01); A61K 31/7036 (2006.01); A61K 31/713 (2006.01); A61K 31/721 (2006.01); A61K 38/08 (2019.01); A61K 38/09 (2006.01); A61K 38/095 (2019.01); A61K 38/12 (2006.01); A61K 38/14 (2006.01); A61K 38/21 (2006.01); A61K 38/22 (2006.01); A61K 38/26 (2006.01); A61K 38/27 (2006.01); A61K 38/28 (2006.01); A61K 38/29 (2006.01); A61K 47/12 (2006.01); A61K 47/14 (2017.01); A61K 47/24 (2006.01); A61K 47/26 (2006.01); A61K 47/32 (2006.01); A61K 9/16 (2006.01); A61K 51/08 (2006.01); A61K 51/10 (2006.01)
CPC A61K 47/44 (2013.01) [A61K 9/0031 (2013.01); A61K 9/0053 (2013.01); A61K 9/10 (2013.01); A61K 9/4858 (2013.01); A61K 9/4866 (2013.01); A61K 9/4891 (2013.01); A61K 31/70 (2013.01); A61K 31/7036 (2013.01); A61K 31/713 (2013.01); A61K 31/721 (2013.01); A61K 38/08 (2013.01); A61K 38/09 (2013.01); A61K 38/095 (2019.01); A61K 38/12 (2013.01); A61K 38/14 (2013.01); A61K 38/212 (2013.01); A61K 38/22 (2013.01); A61K 38/26 (2013.01); A61K 38/27 (2013.01); A61K 38/28 (2013.01); A61K 38/29 (2013.01); A61K 47/12 (2013.01); A61K 47/14 (2013.01); A61K 47/24 (2013.01); A61K 47/26 (2013.01); A61K 47/32 (2013.01); A61K 9/1623 (2013.01); A61K 51/083 (2013.01); A61K 51/1021 (2013.01); A61K 51/1024 (2013.01); A61K 51/1045 (2013.01)] 18 Claims
 
1. A method of treating a subject suffering from acromegaly, the method comprising orally administering to the subject an oral dosage form, comprising:
a composition comprising a suspension which comprises an admixture of a hydrophobic medium and a solid form,
wherein the solid form comprises: a therapeutically effective amount of octreotide, a matrix forming polymer, and a medium chain fatty acid salt, wherein the composition comprises 12% to 21% by weight of the medium chain fatty acid salt, and at least 3% by weight of the matrix forming polymer.